NAMS רווח נקי למניה ב-12 החודשים האחרונים newamsterdampharma.com

NewAmsterdam Pharma revenues are based on the market launch of the innovative Obicetrapib for cholesterol management. This 12-month net income per share chart visualizes this trajectory, where the value of -1.70 reflects this status. The company's strategy relies on creating an affordable oral alternative to injections. Minimal geopolitical influence on the biopharmaceutical sector supports the business's stability.
פילוחים אנליטיים ודוחות נתונים של חברת NewAmsterdam Pharma Corp (NAMS)

This indicator determines the equity value of the asset by calculating the aggregate net income over four quarters per ordinary share. The annual net income per share trend reflects capital management efficiency, while the current negative trend for NewAmsterdam Pharma (NAMS) is driven by development costs for a cholesterol drug, which is standard prior to the commercialization stage.